Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)|DRUG: Eribulin Mesylate
Sponsor: Seoul National University Hospital